aTyr Pharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell aTyr Pharma and other ETFs, options, and stocks.

About ATYR

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. 

CEO
Sanjay S. Shukla
CEOSanjay S. Shukla
Employees
58
Employees58
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
2005
Founded2005
Employees
58
Employees58

ATYR Key Statistics

Market cap
44.83M
Market cap44.83M
Price-Earnings ratio
-0.62
Price-Earnings ratio-0.62
Dividend yield
Dividend yield
Average volume
3.37M
Average volume3.37M
High today
$0.4744
High today$0.4744
Low today
$0.436
Low today$0.436
Open price
$0.455
Open price$0.455
Volume
1.78M
Volume1.78M
52 Week high
$7.29
52 Week high$7.29
52 Week low
$0.395
52 Week low$0.395

Stock Snapshot

aTyr Pharma(ATYR) stock is priced at $0.47, giving the company a market capitalization of 44.83M. It carries a P/E multiple of -0.62.

During the trading session on 2026-06-10, aTyr Pharma(ATYR) shares reached a daily high of $0.47 and a low of $0.44. At a current price of $0.47, the stock is +7.8% higher than the low and still -0.9% under the high.

Trading activity shows a volume of 1.78M, compared to an average daily volume of 3.37M.

Over the past 52 weeks, aTyr Pharma(ATYR) stock has traded between a high of $7.29 and a low of $0.40.

Over the past 52 weeks, aTyr Pharma(ATYR) stock has traded between a high of $7.29 and a low of $0.40.

ATYR News

Simply Wall St 19h
Insider Buyers At aTyr Pharma Likely Disappointed With 19% Slide - simplywall.st

...

Insider Buyers At aTyr Pharma Likely Disappointed With 19% Slide - simplywall.st
TipRanks 1d
aTyr Pharma Granted Nasdaq Extension to Regain Compliance

aTyr Pharma ( (ATYR) ) has provided an announcement. On December 4, 2025, aTyr Pharma, Inc. disclosed that it had received a Nasdaq deficiency notice because i...

TipRanks 6d
Phase 3 Efzofitimod Readout Nears: What ATYR Investors Should Watch in Pulmonary Sarcoidosis

Atyr Pharma Inc. (ATYR) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ra...

Analyst ratings

56%

of 9 ratings
Buy
44.4%
Hold
55.6%
Sell
0%

People also own

Based on the portfolios of people who own ATYR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.